首页> 外文期刊>Clinical journal of gastroenterology >Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection
【24h】

Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection

机译:索拉非尼诱导的多发性肺转移和静脉肿瘤血栓形成的晚期肝细胞癌的完全病理反应,可进行根治性切除

获取原文
获取原文并翻译 | 示例
           

摘要

We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib. A 54-year-old male presented with a large HCC in the right liver with tumor thrombosis of the left portal vein and middle hepatic vein (MHV) as well as multiple lung metastases. His serum alpha-fetoprotein level was elevated at 52,347 ng/mL and palliative treatment with sorafenib was initiated. One month later, a significant reduction in the serum AFP level, decrease in the tumor size with recanalization of the portal vein and the absence of lung metastases were noted. Three months after the start of sorafenib treatment, external-beam radiotherapy was performed to treat enlargement of the area of MHV thrombosis, and the thrombosis regressed.
机译:我们报告的第一例最初不可切除的晚期肝细胞癌(HCC)伴门静脉和肝静脉肿瘤血栓形成以及多处肺转移,可在包括索拉非尼在内的多学科治疗后进行根治性肝切除术。一名54岁的男性患者右肝大肝癌,左门静脉和肝中静脉(MHV)肿瘤血栓形成,并有多处肺转移。他的血清甲胎蛋白水平升高至52,347 ng / mL,并开始了索拉非尼的姑息治疗。一个月后,发现血清AFP水平显着降低,门静脉再通和无肺转移的肿瘤大小减小。索拉非尼治疗开始三个月后,进行了体外放疗以治疗MHV血栓形成区域的扩大,并且血栓形成逐渐消退。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号